AMRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Amneal Pharmaceuticals's change in inventory for the quarter that ended in Dec. 2023 was $-23 Mil. It means Amneal Pharmaceuticals's inventory increased by $23 Mil from Sep. 2023 to Dec. 2023 .
Amneal Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2023 was $-126 Mil. It means Amneal Pharmaceuticals's inventory increased by $126 Mil from Dec. 2022 to Dec. 2023 .
Amneal Pharmaceuticals's Total Inventories for the quarter that ended in Dec. 2023 was $581 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Amneal Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2023 was 123.67.
Inventory Turnover measures how fast the company turns over its inventory within a year. Amneal Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.74.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Amneal Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.94.
The historical data trend for Amneal Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-126 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amneal Pharmaceuticals (NAS:AMRX) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Amneal Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 578.929 | / | 427.154 | * | 365 / 4 | |
= | 123.67 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Amneal Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 427.154 | / | 578.929 | |
= | 0.74 |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Amneal Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 578.929 | / | 616.981 | |
= | 0.94 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew S Boyer | officer: Exec VP, Comm Optns | C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960 |
Tpg Gp A, Llc | 10 percent owner | 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102 |
Gustavo Pesquin | officer: See Remarks | 4 PARK LANE, MADISON NJ 07940 |
Deborah M. Autor | director | C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008 |
Jason B. Daly | officer: SVP, Chief Legal Officer | 400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807 |
Jon Winkelried | 10 percent owner | C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004 |
Gautam Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807 |
Chirag K. Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Chintu Patel | director | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807 |
Nikita Shah | officer: SVP, Chief HR Officer | C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807 |
Joseph Todisco | officer: SVP, Specialty Commercial | 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
John Kiely | director | C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286 |
Jeffrey P. George | director | C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Shlomo Yanai | director | ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073 |
Paul M Meister | director | 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862 |
From GuruFocus
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.